Scarica l'app Stockscreener
25.61
3.31%
0.82
Dopo l'orario di chiusura:
25.61
Precedente Chiudi:
$24.79
Aprire:
$24.57
Volume 24 ore:
1.84M
Relative Volume:
2.03
Capitalizzazione di mercato:
$2.21B
Reddito:
$23.38M
Utile/perdita netta:
$-155.22M
Rapporto P/E:
-17.66
EPS:
-1.45
Flusso di cassa netto:
$-134.36M
1 W Prestazione:
+1.67%
1M Prestazione:
+0.27%
6M Prestazione:
-29.39%
1 anno Prestazione:
-23.67%
Intervallo 1D:
$24.51
$26.49
Intervallo di 1 settimana:
$24.48
$27.15
Portata 52W:
$24.48
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta IDYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
25.61 | 2.21B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Barclays PLC - MarketBeat
Wellington Management Group LLP Lowers Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week LowHere's Why - MarketBeat
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Eastern Progress Online
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - The Eastern Progress Online
Ideaya Biosciences keeps stock target, Outperform on robust medicine pipeline - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Declines By 11.2% - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from Wedbush - MarketBeat
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Par - GuruFocus.com
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - Quantisnow
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - The Malaysian Reserve
IDEAYA nominates IDE251 for cancer treatment development By Investing.com - Investing.com South Africa
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire
IDEAYA nominates IDE251 for cancer treatment development - Investing.com
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers – Company Announcement - Financial Times
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years - Yahoo Finance
Indo-Asian News Service - IANS India Pvt Ltd
State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Consensus Price Target from Analysts - MarketBeat
(IDYA) Proactive Strategies - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week LowShould You Sell? - MarketBeat
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - Kilgore News Herald
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - The Eastern Progress Online
Ideaya Biosciences stock hits 52-week low at $25.16 - Investing.com India
Ideaya Biosciences stock hits 52-week low at $25.16 By Investing.com - Investing.com UK
IDEAYA Biosciences' SWOT analysis: precision oncology stock poised for growth - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
BNP Paribas Financial Markets Decreases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events - Victoria Advocate
IDEAYA begins trial of new cancer drug combo By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - The Eastern Progress Online
IDEAYA begins trial of new cancer drug combo - Investing.com India
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - Marketscreener.com
Ideaya nominates IDE-892 as development candidate - BioWorld Online
IDEAYA Biosciences Unveils IDE892, Breakthrough Cancer Drug Candidate with Promising Preclinical Results - StockTitan
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ideaya Biosciences Inc Azioni (IDYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Throne Jason | Chief Legal Officer |
Jun 27 '24 |
Option Exercise |
7.77 |
53,484 |
415,587 |
63,484 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Option Exercise |
12.86 |
28,500 |
366,510 |
28,500 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Sale |
36.24 |
28,500 |
1,032,884 |
0 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Option Exercise |
4.31 |
83,856 |
361,419 |
761,743 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Option Exercise |
4.31 |
56,711 |
244,424 |
734,598 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Option Exercise |
4.31 |
34,433 |
148,406 |
712,320 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Sale |
42.90 |
83,856 |
3,597,756 |
677,887 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Sale |
41.61 |
56,711 |
2,359,780 |
677,887 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Sale |
41.81 |
34,433 |
1,439,754 |
677,887 |
| Ruiz Briseno Andres | See Remarks |
Feb 09 '24 |
Sale |
46.02 |
2,000 |
92,045 |
24,531 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):